XW143C8Transfusion of Omidubicel into Central Vein, Percutaneous Approach, New Technology Group 8
- Billable / Specific Code
XW143C8 is a billable ICD-10-PCS procedure code for Transfusion of Omidubicel into Central Vein, Percutaneous Approach, New Technology Group 8. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 014. The root operation Transfusion involves putting in blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Administration and transfusion of bone marrow, stem cells, pancreatic islet cells, and t-cells.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 1 | Transfusion |
| 4 | BodyPart | 4 | Central Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | C | Omidubicel |
| 7 | Qualifier | 8 | New Technology Group 8 |
Clinical Classification (CCSR)
AHRQ groups XW143C8 into these clinical categories.
Code History
- 30243X3 — Transfuse Allo Unr Cord Bld Stem Cell in Central Vein, Perc
Similar Procedure Codes
Questions About XW143C8
Is XW143C8 a billable code?
Yes. XW143C8 is a complete seven-character ICD-10-PCS code, specific enough to report Transfusion of Omidubicel into Central Vein, Percutaneous Approach, New Technology Group 8 on inpatient claims from October 1, 2025 through September 30, 2026.
What do the characters in XW143C8 mean?
XW143C8 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 1 is the Operation (Transfusion); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character C is the Device/Substance/Technology (Omidubicel); the 7th character 8 is the Qualifier (New Technology Group 8).
What MS-DRG does XW143C8 group to?
On an inpatient stay, Transfusion of Omidubicel into Central Vein, Percutaneous Approach, New Technology Group 8 maps to MS-DRG 014 (allogeneic Bone Marrow Transplant). The MS-DRG sets the fixed Medicare payment for the stay.
